Logo image of CELC

CELCUITY INC (CELC) Stock Overview

USA - NASDAQ:CELC - US15102K1007 - Common Stock

51.94 USD
-2.04 (-3.78%)
Last: 9/25/2025, 8:26:29 PM
51.94 USD
0 (0%)
After Hours: 9/25/2025, 8:26:29 PM

CELC Key Statistics, Chart & Performance

Key Statistics
52 Week High63.06
52 Week Low7.57
Market Cap2.20B
Shares42.43M
Float34.64M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.45
PEN/A
Fwd PEN/A
Earnings (Next)11-12 2025-11-12/amc
IPO09-20 2017-09-20
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


CELC short term performance overview.The bars show the price performance of CELC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 100 200 300 400

CELC long term performance overview.The bars show the price performance of CELC in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300 400

The current stock price of CELC is 51.94 USD. In the past month the price increased by 3.96%. In the past year, price increased by 260.69%.

CELCUITY INC / CELC Daily stock chart

CELC Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.64 386.06B
AMGN AMGEN INC 12.43 145.99B
GILD GILEAD SCIENCES INC 14.34 137.72B
VRTX VERTEX PHARMACEUTICALS INC 22.54 97.91B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.93B
REGN REGENERON PHARMACEUTICALS 12.17 58.88B
ARGX ARGENX SE - ADR 76.71 43.52B
ONC BEONE MEDICINES LTD-ADR 5.75 39.08B
INSM INSMED INC N/A 28.66B
BNTX BIONTECH SE-ADR N/A 23.58B
NTRA NATERA INC N/A 22.46B
BIIB BIOGEN INC 8.47 19.89B

About CELC

Company Profile

CELC logo image Celcuity, Inc. operates as a cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 87 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.

Company Info

CELCUITY INC

16305 36th Ave N Ste 100

Minneapolis MINNESOTA 55446 US

CEO: Brian F. Sullivan

Employees: 87

CELC Company Website

CELC Investor Relations

Phone: 17633920767

CELCUITY INC / CELC FAQ

What is the stock price of CELCUITY INC today?

The current stock price of CELC is 51.94 USD. The price decreased by -3.78% in the last trading session.


What is the ticker symbol for CELCUITY INC stock?

The exchange symbol of CELCUITY INC is CELC and it is listed on the Nasdaq exchange.


On which exchange is CELC stock listed?

CELC stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CELCUITY INC stock?

14 analysts have analysed CELC and the average price target is 70.82 USD. This implies a price increase of 36.34% is expected in the next year compared to the current price of 51.94. Check the CELCUITY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CELCUITY INC worth?

CELCUITY INC (CELC) has a market capitalization of 2.20B USD. This makes CELC a Mid Cap stock.


How many employees does CELCUITY INC have?

CELCUITY INC (CELC) currently has 87 employees.


What are the support and resistance levels for CELCUITY INC (CELC) stock?

CELCUITY INC (CELC) has a support level at 51.87 and a resistance level at 53.55. Check the full technical report for a detailed analysis of CELC support and resistance levels.


Should I buy CELCUITY INC (CELC) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CELCUITY INC (CELC) stock pay dividends?

CELC does not pay a dividend.


When does CELCUITY INC (CELC) report earnings?

CELCUITY INC (CELC) will report earnings on 2025-11-12, after the market close.


What is the Price/Earnings (PE) ratio of CELCUITY INC (CELC)?

CELCUITY INC (CELC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.45).


What is the Short Interest ratio of CELCUITY INC (CELC) stock?

The outstanding short interest for CELCUITY INC (CELC) is 16.23% of its float. Check the ownership tab for more information on the CELC short interest.


CELC Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to CELC. When comparing the yearly performance of all stocks, CELC is one of the better performing stocks in the market, outperforming 99.06% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CELC Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to CELC. The financial health of CELC is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CELC Financial Highlights

Over the last trailing twelve months CELC reported a non-GAAP Earnings per Share(EPS) of -3.45. The EPS decreased by -25.91% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -81%
ROE -335.12%
Debt/Equity 2.24
Chartmill High Growth Momentum
EPS Q2Q%-67.74%
Sales Q2Q%N/A
EPS 1Y (TTM)-25.91%
Revenue 1Y (TTM)N/A

CELC Forecast & Estimates

14 analysts have analysed CELC and the average price target is 70.82 USD. This implies a price increase of 36.34% is expected in the next year compared to the current price of 51.94.


Analysts
Analysts85.71
Price Target70.82 (36.35%)
EPS Next Y-36.8%
Revenue Next YearN/A

CELC Ownership

Ownership
Inst Owners77.74%
Ins Owners11.21%
Short Float %16.23%
Short Ratio3.66